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Unsupervised Exercise and Mobility Loss in Peripheral Artery Disease:
A Randomized Controlled Trial
Mary M. McDermott, MD; Jack M. Guralnik, MD, PhD; Michael H. Criqui, MD, MPH; Luigi Ferrucci, MD, PhD; Kiang Liu, PhD;
Bonnie Spring, PhD; Lu Tian, ScD; Kathryn Domanchuk, BS; Melina Kibbe, MD; Lihui Zhao, PhD; Donald Lloyd Jones, MD, ScM;
Yihua Liao, MS; Ying Gao, MS; W. Jack Rejeski, PhD
Background-—Few medical therapies improve lower extremity functioning in people with lower extremity peripheral artery disease
(PAD). Among people with PAD, we studied whether a group-mediated cognitive behavioral intervention promoting home-based
unsupervised exercise prevented mobility loss and improved functional performance compared to control.
Methods and Results-—One hundred ninety-four PAD participants were randomized. During months 1 to 6, the intervention group
met weekly with other PAD participants and a facilitator. Group support and self-regulatory skills were used to help participants
adhere to walking exercise. Ninety-percent of exercise was conducted at or near home. The control group attended weekly
lectures. During months 6 to 12, each group received telephone contact only. Primary outcomes have been reported. Here we
compare changes in exploratory outcomes of mobility loss (the inability to climb a flight of stairs or walk one-quarter mile without
assistance), walking velocity, and the Short Physical Performance Battery. Compared to controls, fewer participants randomized to
the intervention experienced mobility loss at 6-month follow-up: 6.3% versus 26.5%, P=0.002, odds ratio=0.19 (95% CI=0.06 to
0.58) and at 12-month follow-up: 5.2% versus 18.5%, P=0.029, odds ratio=0.24 (95% CI=0.06 to 0.97). The intervention improved
fast-paced 4-m walking velocity at 6-month follow-up (P=0.005) and the Short Physical Performance Battery at 12-month follow-up
(P=0.027), compared to controls.
Conclusions-—In exploratory analyses, a group-mediated cognitive behavioral intervention promoting unsupervised walking
exercise prevented mobility loss and improved functioning at 6- and 12-month follow-up in PAD patients.
Clinical Trial Registration-—URL: http://clinicaltrials.gov. Unique identifier: NCT00693940. ( J Am Heart Assoc. 2015;4:
e001659 doi: 10.1161/JAHA.114.001659)
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F unctional decline and mobility loss are common in peoplewith lower extremity peripheral artery disease (PAD),1–4
but few medical therapies have been identified that improve
these outcomes in PAD. Supervised treadmill exercise
improves walking endurance in people with PAD.5,6 However,
most PAD patients do not participate in supervised treadmill
exercise.7 This is likely because most medical insurance
companies do not pay for supervised treadmill exercise in
people with PAD and because traveling to an exercise facility
for regular supervised exercise is burdensome.7
Interventions that promote exercise outside of a super-
vised setting and are tailored to the individual could be
effective and convenient therapy for patients with PAD.
Interventions that promote unsupervised exercise at home
should be more accessible and acceptable to PAD patients
than supervised exercise because unsupervised exercise at
home is relatively inexpensive and does not require travel to
an exercise facility 3 times weekly.
Walking-related ischemic leg pain makes consistent adher-
ence to walking exercise programs challenging for PAD
patients. This may be particularly true in an unsupervised
setting without encouragement from a coach. Small studies
completed in the late 20th century suggested that home-
based walking exercise programs had unclear or no efficacy
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for improving walking performance in PAD.8–10 An uncon-
trolled 6-month trial from the Netherlands showed significant
improvement in treadmill walking time in PAD patients who
were referred to a physical therapy program that provided
supervised treadmill exercise 2 to 3 times per week, tapering
over time to supervised exercise once every 2 weeks.11 Three
recent larger randomized trials demonstrated that interven-
tions designed to help PAD patients adhere to home-based
walking exercise improved treadmill walking performance
and/or the 6-minute walk in people with PAD.12–14 However,
unanswered questions remain. First, it is unclear whether
unsupervised home-based exercise is sustainable. Two of the
3 recent trials were only 12 weeks in duration.13,14 Second,
the 3 recent home-based exercise trials focused on outcomes
of treadmill walking performance and the 6-minute walk. Little
is known about other clinically meaningful functional out-
comes that may be improved by interventions that increase
unsupervised home-based exercise in PAD.
We recently reported results of the Group Oriented Arterial
Leg Study (GOALS), a randomized trial that demonstrated that
a group-mediated cognitive behavioral (GMCB) intervention,
designed to promote home-based unsupervised walking
exercise, significantly increased 6-minute walk distance,
treadmill walking time, and physical activity in patients with
PAD.12 The GOALS intervention also improved the 6-minute
walk at 12-month follow-up.15 The GMCB intervention used a
structured intervention to encourage exercise in an unsuper-
vised setting near home. The intervention consisted of a
minimum of 260 exercise bouts over 12 months, 90% of
which occurred at or near home in an unsupervised setting.
Here we report the effect of the GOALS GMCB intervention
on the exploratory outcomes of participant-reported mobility
loss and participant-reported gain in mobility at 6- and 12-
month follow-up in participants with PAD. In contrast to
objective measures obtained in controlled settings, mobility
loss measures participants’ perceptions of their capacity in
daily life. Mobility loss is a well-validated and clinically
meaningful outcome that is associated with an increased risk
of nursing home placement, depression, cognitive impair-
ment, obesity, and chronic disease.16–20 We also report the
effect of the GOALS exercise intervention on the objective
measures of walking velocity and the Short Physical Perfor-
mance Battery (SPPB) at 6- and 12-month follow-up. Slower
walking velocity and lower SPPB scores are associated with
higher rates of mobility loss and/or mortality in people with
and without PAD.1,21–25 We hypothesized that (1) the GMCB
intervention, designed to increase home-based exercise,
would prevent mobility loss and improve mobility impairment
compared to the control group in people with PAD and that
(2) the GMCB intervention would increase or prevent decline
in walking velocity and the SPPB, compared to the control
group.
Methods
Methods of the GOALS randomized trial have been
reported.12,15,26 The Institutional Review Board at Northwest-
ern University approved the protocol, and participants
provided written informed consent.
Participant Identification
The study was performed in Chicago, IL between July 22,
2008 and May 2, 2013. Recruitment methods included
newspaper and radio advertisements and mailed postcards to
individuals age 65 and older living in the Chicago area.12,15,26
Overview of Study Design
Participants were randomized to 1 of 2 groups: a GMCB
intervention, designed to help participants adhere to home-
based unsupervised walking exercise versus an attention
control group. During Phase I of the trial (months 1 to 6),
participants randomized to the intervention attended weekly
group meetings led by a facilitator at an exercise center.
Participants were instructed to walk for exercise a minimum
of 5 days per week, with only 1 session per week conducted
at the center with their group. During the on-site weekly
sessions, group support and self-regulatory skill instructions
were employed to help participants adhere to unsupervised
home-based walking exercise. Participants randomized to the
control group attended weekly group meetings at the medical
center, during which they received educational lectures on
health topics unrelated to exercise. Primary outcomes were
measured at 6-month follow-up and have been reported.12
During Phase II (months 7 to 12), participants randomized to
the study intervention received telephone calls from their
group facilitator. Participants were encouraged to continue
walking for exercise a minimum of 5 days per week. Of the
minimum of 260 exercise bouts prescribed in the intervention
over 12 months, only 26 of the exercise bouts took place at
the study exercise center. Thus, 90% of the prescribed
walking intervention sessions took place in a home-based
unsupervised setting.12,15 Participants randomized to the
control group received telephone calls from a study coordi-
nator with information related to the educational sessions in
Phase I. Follow-up testing was performed at 6- and 12-month
follow-up.
Inclusion and Exclusion Criteria
All participants had an ankle brachial index (ABI) ≤0.90 in
either leg or a resting ABI ≥0.91 and ≤1.00 with a ≥20% drop
in ABI following a heel-rise test.27 Prior studies show that
measuring the ABI after heel-rise exercises gives results
DOI: 10.1161/JAHA.114.001659 Journal of the American Heart Association 2
Randomized Trial of Unsupervised Exercise in PAD McDermott et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
comparable to measuring the ABI after treadmill testing.27,28
For example, Amirhamzeh et al showed that in a group of 14
PAD patients with symptoms of intermittent claudication but
ABIs >0.80, the ankle systolic blood pressure changes with
the 2 methods were of similar magnitude, with a mean drop of
21% on the treadmill and 19% after heel-rise.27 Similarly,
McPhail reported that in a study of 50 consecutive patients
with suspected peripheral artery disease, the correlation
between the 2 methods was outstanding, with a Pearson
correlation coefficient of r=0.95 (95% CI 0.93 to 0.97). These
studies demonstrate the validity of the heel-rise testing as an
alternative to treadmill testing for identifying PAD. Partici-
pants with a resting ABI >0.90 were included if they had
medical-record-documented lower extremity revascularization
or evidence of PAD from an accredited vascular laboratory.
Evidence of PAD from an accredited vascular laboratory
consisted of an ABI <0.90 or a toe brachial index <0.70. No
other vascular laboratory criteria were used to diagnose PAD.
Exclusion criteria have been reported.26 Briefly, potential
participants with below- or above-knee amputation, wheel-
chair confinement, inability to walk at least 50 feet without
stopping, significant cognitive impairment, and inability to
return weekly to the medical center for the first 6 months of
the intervention were excluded. However, potential partici-
pants were still included if they were able to attend most (but
not all) of the weekly sessions during the first 6 months of the
intervention. Individuals dependent on a walking aid other
than a cane, those whose walking impairment was due to a
condition other than PAD, those with severe visual or hearing
impairment, those with foot ulcer or critical limb ischemia,
and those who did not complete the study’s run-in phase were
excluded. Individuals who recently had undergone major
surgery or lower extremity revascularization and those
anticipating major surgery or lower extremity revasculariza-
tion in the next 12 months were excluded. Participants
already exercising at a comparable level to that targeted by
the exercise intervention, those who required oxygen during
activity or exercise, those who recently completed cardiac
rehabilitation, and those with a history of Parkinson’s disease
were excluded. To screen for coronary artery disease prior to
randomization, all participants underwent a baseline regular
exercise stress test. Potential participants with an abnormal
baseline exercise stress test were excluded, unless additional
cardiac work-up by their individual physician showed no
evidence of significant coronary ischemia.
ABI Measurement
A hand-held Doppler probe (Pocket Dop II; Nicolet Biomedical
Inc, Golden, CO) was used to obtain systolic pressures twice
in the brachial, dorsalis pedis, and posterior tibial arteries
using established methods.29,30
Medical History and Body Mass Index
Medical history, race, and demographics were obtained
through patient report using questionnaires administered in
a standardized fashion. Height and weight were measured at
baseline. Body mass index was calculated as weight (kg)/
[height (m)]2.26
Leg Symptoms
Even people with PAD who are asymptomatic have significant
functional impairment, compared to those without PAD.3,4
Therefore, people with PAD were eligible, regardless of
whether or not they had classic intermittent claudication
(IC) symptoms. Leg symptoms were classified using the San
Diego claudication questionnaire.31 Intermittent claudication
was defined as exertional calf pain that did not begin at rest,
caused the patient to stop walking, and resolved within
10 minutes of rest.2–4,31 Participants without intermittent
claudication either reported no exertional leg symptoms
(asymptomatic PAD) or had leg symptoms that did not meet
the criteria of intermittent claudication.2–4,31
Outcomes
Mobility measures
At baseline and at each follow-up visit, participants were
asked whether they were able to walk up and down stairs to
the second floor and walk one-quarter mile (3 blocks), “on
their own,” “with help,” or “not at all,” Mobility impairment
was defined as reporting either needing help or the inability
to (1) walk up and down a flight of stairs or (2) walk one
quarter mile.1,22,23 Mobility loss was defined as reporting the
inability to walk up and down 1 flight of stairs or walk one
quarter mile either “at all” or “without assistance” during
follow-up among participants without mobility impairment at
baseline.1,22,23 We also studied rates of regaining mobility in
the exercise and control groups, by determining the propor-
tion of participants with mobility impairment at baseline who
reported being able to both (1) walk up and down 1 flight of
stairs and (2) walk one quarter mile without assistance at the
6- or 12-month follow-up visits. Participants’ report of their
mobility is valid and reliable.32,33 When patient-reported
measures of mobility were tested 3 weeks apart, agreement
was 89%.33 Patient-reported mobility loss predicted rates of
nursing home admission, disability, and mortality in the
Established Populations for the Epidemiologic Study of the
Elderly.22 Furthermore, mobility loss measures patient per-
ception of their functional performance in daily life, in
contrast to objective assessments that are measured in
controlled settings.
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Short Physical Performance Battery (SPPB)
The SPPB consists of the usual paced 4-m walking velocity,
repeated chair rises, and standing balance. A score of 0 to 4 is
assigned for each task according to established methods,
with a score of 0 assigned for tasks that are not able to be
completed.22,25 Scores from the 3 components are summed
to obtain a total SPPB score ranging from 0 to 12. Lower
SPPB scores are associated with higher rates of mobility loss
and mortality in people with PAD.1,21,22
Four-meter walking velocity. For usual-paced walking
velocity, participants were timed walking a 4-m distance after
instructions to walk at their “usual pace, as if walking down
the street to go to the store.” Participants were also timed
walking 4 m after instructions to walk at their “fastest pace.”
Each 4-m walk was performed twice, and the faster of the 2
trials for each test was used for analyses.1,21,22
Repeated chair rises. Participants sat in a chair and were
instructed to fold their arms across their chest and stand 5
times as quickly as possible. Time to complete 5 consecutive
chair rises was measured.1,21,22
Standing balance. Participants were instructed to perform 3
standing positions for 10 seconds each: side-by-side (stand-
ing with feet parallel and touching), semitandem (standing
with feet parallel with the heel of 1 foot touching the base of
the big toe of the other foot), and tandem (standing with 1
foot directly in front of the other, with the heel of the front
foot touching the tips of the toes on the opposite foot).1,21,22
Participants received a score of “1” if they could hold the side-
by-side stand for 10 seconds but could not hold the
semitandem stand for 10 seconds. Participants received a
score of “2” if they could hold the semitandem stand for
10 seconds but could not hold the tandem stand for more
than 2 seconds. Participants received a score of “3” if they
held the semitandem stand for 10 seconds and held the
tandem stand for >2 to 9 seconds. Participants received a
score of “4” if they could hold the tandem stand for a full
10 seconds.22
Study Interventions
During Phase I (months 1 to 6) of the GMCB intervention,
participants met weekly for 90 minutes with a group of PAD
participants and a trained facilitator.12,26 Transportation was
provided. At the first sessions, participants were instructed to
walk for exercise a minimum of 5 times weekly, with 4 of the
5 sessions per week during the first 6 months conducted at
or near home in an unsupervised setting. Participants were
instructed to begin with 15 minutes of walking exercise per
exercise bout, working up to 50 minutes per exercise bout.
Thus, during the first 6 months, the intervention was designed
such that a minimum of 80% of exercise sessions were
conducted at home in an unsupervised setting. At the weekly
on-site meetings, the facilitator led discussions on a different
topic each week, using principles from social cognitive theory,
group dynamics, and self-regulation to motivate participants
and help them acquire behavioral skills needed to adhere to
unsupervised home-based exercise.34–36 Participants were
instructed to walk for exercise at least 5 days per week at
home, working up to 50 minutes of exercise per day. With
each participant, the group facilitator discussed potential
locations for exercising at or near the participant’s home.
Home exercise locations were primarily based on each
participant’s preference.
Phase I: control group
Participants in the control group attended weekly health
education sessions with other PAD participants during Phase
I. Healthcare professionals gave lectures on topics including
cholesterol, cancer prevention, and nutrition.
Phase II: intervention and control groups
During Phase II (months 7 to 12), there were no on-site
sessions. Instead, participants received regularly scheduled
telephone calls. In the exercise group, the telephone calls
were designed to reinforce self-regulation principals empha-
sized in Phase I and to encourage continued home-based
exercise. As during the first 6 months, participants were
instructed to walk for exercise a minimum of 5 times per
week. Participants were asked to continue to record their
daily walking exercise activity and mail their written walking
exercise logs back to study investigators. For participants in
the control group, telephone calls reviewed health education
topics covered during Phase I. Telephone calls lasted
10 minutes and occurred every 2 weeks during 7 to
9 months and monthly once during 10 to 12 months.
Sample Size Calculations
Outcomes for this report are exploratory, were not prespec-
ified, and therefore power calculations were not performed.
Statistical Analyses
Analyses comparing rates of mobility loss between the
exercise and control groups during follow-up were limited to
participants without mobility impairment at baseline. We
performed 3 sets of analyses for the outcome of mobility loss.
First, among participants without mobility impairment at
baseline, we compared the proportion of participants in the
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exercise versus control groups who reported mobility loss
(inability to either walk one-quarter mile or walk up and down
a flight of stairs without assistance) at the 6- and 12-month
follow-up visits, respectively. Second, among participants
without mobility impairment at baseline, we compared rates
of cumulative mobility loss during follow-up, by reporting the
proportion of participants at 12-month follow-up who reported
mobility loss at either the 6- or 12-month follow-up. Third,
among participants without mobility impairment at baseline,
we compared the proportion of participants who reported
mobility loss at both the 6- and 12-month follow-up visits (ie,
persistent mobility loss).
Analyses comparing rates of regaining mobility were
performed among participants who reported mobility loss at
baseline (ie, those who reported inability or needing help in
walking up and down a flight of stairs or walking one-quarter
mile without assistance at baseline). We performed 3 sets of
analyses. First, among participants with mobility loss at
baseline, we compared the proportion of participants in the
exercise and control groups who reported no mobility loss at
the time of their 6-month follow-up visit and no mobility loss
at the time of their 12-month follow-up visits, respectively.
Second, among participants with mobility loss at baseline, we
compared the proportion of participants in the exercise and
control groups at 12-month follow-up who reported no
mobility loss in at least 1 of their follow-up visits (ie, either
the 6- or the 12-month follow-up visit). Third, among
participants with mobility loss at baseline, we compared the
proportion of participants in the exercise and control groups
at 12-month follow-up with persistently improved mobility,
defined as those without mobility loss at both 6-month and
12-month follow-up.
Chi-square tests and 2-sample 2-sided t tests were used to
compare categorical and continuous characteristics of par-
ticipants in the exercise and control groups, respectively, who
completed 6- or 12-month follow-up. For mobility loss, we
performed logistic regression to obtain odds ratios of mobility
loss between the exercise and control groups at 6- and 12-
month follow-up, among those without mobility loss at
baseline. For regaining mobility, we performed logistic
regression to obtain odds ratios for regaining mobility
between the exercise and control groups, among those with
mobility loss at baseline. The exact method is used when
appropriate. Two sample, 2-sided t tests were used to
compare changes in 4-m walking velocity, the SPPB, and
each individual component of the SPPB between baseline and
6-month follow-up and between baseline and 12-month
follow-up between the exercise and the control group. A
priori, the P value considered statistically significant was
P<0.05. Intention-to-treat analyses were performed. These
comparisons were not prespecified and no adjustment for
Type I error was made despite multiple comparisons.
All participants were asked to return for follow-up
measurements, regardless of their adherence to interven-
tions. Decedents were excluded from analyses. In addition, we
performed sensitivity analyses for missing data due to loss to
follow-up. First, we used multiple imputation to impute the
missing outcome data at 6- and 12-month follow-up, under
the assumption of missing at random. Second, to examine
whether the results for mobility loss are sensitive to potential
informative missing due to loss to follow-up, we conserva-
tively imputed the missing outcome data using the worst
values. Specifically, the missing mobility status was imputed
as mobility loss, and the missing 4-m walking velocity, the
SPPB, and each individual component of the SPPB were
imputed as their corresponding lowest observed values at
each follow-up visit. Analyses were performed using SAS
version 9.4.
Results
One hundred ninety-four participants were randomized to the
intervention (N=97) or the control group (N=97). Attendance
rates for the weekly on-site sessions during the first 6 months
of the intervention were 76.5% in the intervention group and
72.4% in the control group. Of the 194 participants random-
ized, 178 (91.8%) completed 6-month follow-up and 168
(86.6%) completed 12-month follow-up testing (Figure 1).
Table 1 compares characteristics of the exercise and
control groups among participants who completed 6- and/
or 12-month follow-up testing for 1 or more of the
outcomes reported here. Characteristics of participants
are shown for the cohort overall (N=178) and for partic-
ipants with (N=46) and without (N=132) mobility loss at
baseline. There were no differences between the 2 groups
at baseline (Table 1).
Among the 194 participants, 70 participants randomized to
the exercise group and 70 randomized to the control group
reported no mobility loss at baseline. Of these, 132
completed 6-month follow-up testing and 123 completed
12-month follow-up. At 6-month follow-up, 4/64 (6.3%) of
participants in the exercise group versus 18/68 (26.5%) in the
control group reported new mobility loss (odds ratio=0.19,
95% CI=0.06 to 0.58, P=0.002) (Figure 2). At 12-month
follow-up, 3/58 (5.2%) participants in the exercise group
versus 12/65 (18.5%) in the control group reported mobility
loss (odds ratio=0.24, 95% CI=0.06 to 0.97, P=0.029)
(Figure 2). Cumulative rates of mobility loss, defined as the
presence of mobility loss at either the 6-month or 12-month
follow-up visit, were 5/58 (8.6%) in the exercise group versus
22/65 (33.9%) in the control group (odds ratio=0.18, 95%
CI=0.06 to 0.53, P<0.001). Rates of persistent mobility loss,
defined as mobility loss at both the 6- and 12-month follow-up
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visits among individuals without mobility loss at baseline,
were 2/58 (3.5%) in the exercise versus 6/65 (9.2%) in the
control group (odds ratio=0.35, 95% CI=0.07 to 1.81,
P=0.194).
Among participants without mobility loss at baseline,
incidence rates of reporting difficulty or inability to walk one-
quarter mile without assistance were 1/69 (1.5%) in the
exercise group versus 16/70 (22.9%) in the control group
Eligible for baseline 
testing
Excluded (n = 1128)
ABI>0.90 without prior diagnosis or    
adequate heel-rise ABI (n = 494)
Did not attend baseline or lost    
interest (n = 474)
Poor health (n = 31)  
Abnormal baseline stress test (n = 30)
Walking limited by non-PAD condition 
(n = 26)
Unwilling to participate in control arm 
(n = 17)
Already walking regularly (n = 15)
Dementia (n = 10)
Failure to complete run-in (n = 9)
Use of walker (n = 8)
Revascularization planned in next year (n    
= 4)
Physician indicates no PAD (n = 2)
Foot ulcer (n = 1)
Use of oxygen tank (n = 1)
Major illness in past year (n = 1)
Revascularization in previous 3 months   
(n = 1) 
Unable to speak English (n = 1)
Current participation in cardiac rehab 
(n = 1) 
Current participation in another trial 
(n = 1)
Significant visual impairment (n = 1)
Randomized (n = 194)
Allocated to walking exercise 
intervention (n = 97)
Received allocated 
intervention (n = 95)
Did not receive allocated 
intervention 
Lost interest (n = 2)
A
llo
ca
tio
n
E
nr
ol
lm
en
t
Allocated to attention control 
(n = 97)
Received allocated intervention 
(n = 92)
Did not receive allocated 
intervention
Lost interest (n = 5)
Fo
llo
w
-u
p
Lost to 6-month follow-up 
(n = 9)
Lost interest (n = 8)
Death (n = 1)
Discontinued intervention
(n = 10) 
Lost interest (n = 5)
Personal problems (n = 3)
Illness (n = 2)
Lost to 12-month follow-up 
(n = 16)
Lost interest (n = 13)
Death (n = 3)
Lost to 6-month follow-up 
(n = 7)  
Lost interest (n = 5)
Death (n = 2)
Discontinued intervention 
(n = 7) 
Lost interest (n = 4)
Illness (n = 2)
Moved (n = 1)
Lost to 12-month follow-up 
(n = 10)  
Lost interest (n = 8)
Death (n = 2)
Included in 6-month analysis 
(n=88)
Excluded from 6-month 
analysis (n=9)
Lost interest (n=8)
Death (n=1)
Included in 12-month 
analysis (n = 81)
Excluded from12-month
analysis (n = 16) 
Lost interest (n = 13)
Death (n = 3)
Included in 6-month analysis 
(n=90)
Excluded from 6-month 
analysis (n=7)
Lost interest (n=5)
Death (n=2)
Included in 12-month analysis
(n = 87)
Excluded from12-month
analysis (n = 10) 
Lost interest (n = 8)
Death (n = 2)
A
na
ly
se
s
Figure 1. Overview of study design for the GOALS randomized trial. Adapted with permission from
McDermott et al.12 ABI indicates ankle brachial index; GOALS, Group Oriented Arterial Leg Study; PAD,
peripheral artery disease.
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(odds ratio=0.05, 95% CI=0.00 to 0.32, P<0.001) at 6-month
follow-up and 3/62 (4.8%) in the exercise group versus 12/67
(17.9%) in the control group (odds ratio=0.23, 95% CI=0.05 to
0.93, P=0.027) at 12-month follow-up. Among participants
without mobility loss at baseline, rates of reporting difficulty
or the inability to climb a flight of stairs without assistance
were 3/77 (3.9%) in the exercise group versus 8/83 (9.6%) in
the control group (odds ratio=0.38, 95% CI=0.08 to 1.69,
P=0.214) at 6-month follow-up and 3/71 (4.2%) in the
intervention versus 2/80 (2.5%) in the control group (odds
ratio=1.72, 95% CI=0.26 to 14.17, P=0.666) at 12-month
follow-up. Thus, most of the benefit of the exercise interven-
tion on preventing mobility loss was due to preserving the
ability to walk one-quarter mile without assistance.
Fifty-four participants (27 in the exercise group and 27 in
the control group) reported mobility loss at baseline. Of these,
46 completed 6-month follow-up and 45 completed 12-month
follow-up. At 6-month follow-up, 17/24 (70.8%) of partici-
pants in the exercise group and 7/22 (31.8%) of participants
in the control group reported no mobility loss (odds
ratio=5.20, 95% CI=1.48 to 18.29, P=0.008). At 12-month
follow-up, 16/23 (69.6%) of participants in the exercise group
and 4/22 (18.2%) of participants in the control group reported
no mobility loss (odds ratio=10.29, 95% CI=2.53 to 41.75,
P<0.001) (Figure 3). Cumulative rates of regaining mobility,
defined as reporting no mobility loss at either the 6-month or
12-month follow-up visits among people with mobility loss at
baseline, were 19/23 (82.6%) in the exercise versus 8/22
Table 1. Characteristics of Peripheral Artery Disease Participants Randomized to the Home-Based Exercise Versus the Control
Groups Overall and According to Presence Versus Absence of Baseline Mobility Impairment
Entire Cohort
Participants Without Mobility
Impairment at Baseline
Participants With Mobility
Impairment at Baseline
Intervention
Group
(N=88)
Control
Group
(N=90)
Intervention
Group
(N=64)
Control
Group
(N=68)
Intervention
Group
(N=24)
Control
Group
(N=22)
Age (y), mean (SD) 69.7 (9.3) 71.6 (9.5) 69.5 (8.9) 71.1 (9.6) 70.2 (10.6) 73.2 (9.4)
Male sex, n (%) 44 (50) 44 (48.89) 38 (59.38) 39 (57.35) 6 (25) 5 (22.73)
African American race, n (%) 49 (55.68) 38 (42.22) 29 (45.31) 26 (38.24) 20 (83.33) 12 (54.55)
White race, n (%) 37 (42.1) 49 (55.4) 33 (51.6) 40 (58.8) 4 (16.7) 9 (40.9)
Asian race, n (%) 1 (1.1) 3 (3.33) 1 (1.6) 2 (2.9) 0 (0) 1 (4.6)
More than one race, n (%) 1 (1.1) 0 (0) 1 (1.6) 0 (0) 0 (0) 0 (0)
Hispanic or Latino ethnicity, n (%) 4 (4.6) 3 (3.3) 4 (6.3) 3 (4.4) 0 (0) 0 (0)
Not Hispanic or Latino, n (%) 84 (95.5) 87 (96.7) 60 (93.8) 65 (95.6) 24 (100) 22 (100)
Ankle brachial index, mean (SD) 0.67 (0.16) 0.68 (0.18) 0.69 (0.16) 0.71 (0.17) 0.61 (0.16) 0.59 (0.16)
Current smoker, n (%) 22 (25) 17 (18.89) 16 (25) 13 (19.12) 6 (25) 4 (18.18)
Body mass index, mean (SD) 28.6 (6.5) 29.1 (6.7) 28.2 (6.4) 29.3 (6.2) 29.4 (7.0) 28.5 (8.1)
Angina, n (%) 15 (17.05) 14 (15.73) 9 (14.06) 11 (16.18) 6 (25) 3 (14.29)
Myocardial infarction, n (%) 11 (12.5) 13 (14.44) 6 (9.38) 10 (14.71) 5 (20.83) 3 (13.64)
Heart failure, n (%) 9 (10.23) 11 (12.22) 4 (6.25) 8 (11.76) 5 (20.83) 3 (13.64)
Diabetes, n (%) 26 (29.55) 34 (37.78) 18 (28.13) 25 (36.76) 8 (33.33) 9 (40.91)
Classic symptoms of intermittent claudication, n (%) 27 (30.68) 21 (23.33) 20 (31.25) 17 (25) 7 (29.17) 4 (18.18)
Leg symptoms other than intermittent
claudication, n (%)
54 (61.36) 61 (67.78) 38 (59.38) 43 (63.24) 16 (66.67) 18 (81.82)
No exertional leg symptoms, n (%) 7 (7.95) 8 (8.89) 6 (9.38) 8 (11.76) 1 (4.17) 0 (0)
Lack of mobility impairment at baseline, n (%) 64 (72.73) 68 (75.56) 64 (100) 68 (100) 0 (0) 0 (0)
Usual-paced 4-m walking velocity (m/s), mean (SD) 0.91 (0.18) 0.88 (0.15) 0.95 (0.16) 0.90 (0.16) 0.79 (0.18) 0.82 (0.10)
Fastest paced 4-m walking velocity (m/s), mean (SD) 1.24 (0.28) 1.22 (0.22) 1.31 (0.25) 1.26 (0.22) 1.07 (0.29) 1.10 (0.18)
Short Physical Performance Battery (0 to 12 score,
12=best), mean (SD)
9.84 (2.25) 9.81 (1.92) 10.31 (1.75) 10.07 (1.89) 8.52 (2.92) 9.00 (1.83)
Statin use, n (%) 37 (42.1) 48 (53.3) 28 (43.8) 36 (52.9) 9 (37.5) 12 (54.6)
Cilostazol use, n (%) 1 (1.1) 7 (7.8) 1 (1.6) 4 (5.9) 0 (0) 3 (13.6)
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(36.4%) in the control group (odds ratio=8.31, 95% CI=2.08 to
33.19, P=0.002). Rates of persistent gains in mobility, defined
as participants without mobility loss at both the 6- and 12-
month follow-up among those reporting mobility loss at
baseline, were 14/23 (60.9%) in the exercise group and 3/22
(13.6%) in the control group (odds ratio=9.85, 95% CI=1.99 to
46.93, P=0.002).
Among participants with mobility loss at baseline, rates of
becoming able to walk one-quarter mile without assistance
were 14/19 (73.7%) in the exercise group versus 8/20
(40.0%) in the control group (odds ratio=4.20, 95% CI=1.08 to
16.32, P=0.034) at 6-month follow-up and 14/19 (73.7%) in
the exercise versus 3/20 (15.0%) in the control group (odds
ratio=15.87, 95% CI=3.00 to 81.96, P<0.001) at 12-month
follow-up (Figure 3). Among participants with mobility loss at
baseline, rates of becoming able to climb a flight of stairs
without assistance were 7/11 (63.6%) in the exercise group
versus 4/7 (57.1%) in the control group (odds ratio=1.31, 95%
CI=0.17 to 10.37, P=1.00) at 6-month follow-up and 7/10
(70.0%) in the exercise versus 4/7 (57.1%) in the control
group (odds ratio=1.75, 95% CI=0.21 to 14.29, P=0.644) at
12-month follow-up (Figure 3). Thus, most of the benefit of
exercise on regaining mobility was related to resuming the
ability to walk one-quarter mile without assistance.
Figure 4 compares changes over time in fast-paced 4-m
walking velocity, usual-paced 4-m walking velocity, and the
SPPB in the intervention and control groups. The intervention
group improved their fast-paced 4-m walking velocity at
6-month follow-up: 1.24 to 1.29 m/s in the exercise group
versus 1.22 to 1.19 m/s in the control group (mean
difference +0.08, 95% CI=+0.02 to +0.13, P=0.005). The
exercise group did not improve their usual paced 4-m walking
velocity at 6-month follow-up compared to the control group:
0.90 to 0.94 m/s in the exercise group versus 0.88 to
0.89 m/s in the control group (mean difference +0.03, 95%
CI=0.004 to +0.07, P=0.080) at 6-month follow-up.
Additionally, there were no associations of exercise with
improvement in usual-paced or fast-paced 4-m walking
velocity at 12-month follow-up (Figure 4).
There was no difference in change in the SPPB score at
6-month follow-up between the exercise and the control
group: 9.87 to 10.33 in the exercise group versus 9.93 to
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Figure 2. Rates of new mobility loss in the exercise and control groups among people with peripheral artery disease. Analyses are limited to
people without mobility loss at baseline.
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9.95 in the control group (mean difference +0.44, 95%
CI=0.06 to +0.94, P=0.086). The exercise group had
significant improvement in the SPPB at 12-month follow-up:
9.87 to 10.33 in the exercise group versus 9.93 to 9.81 in the
control group (mean difference +0.58, 95% CI=+0.07 to
+1.09, P=0.027). Table 2 shows changes in individual com-
ponents of the SPPB in the exercise versus control groups
(Table 2).
Between baseline and 6-month follow-up, 3/88 (3.4%) of
the intervention group versus 4/90 (4.4%) of the control
group underwent lower extremity revascularization. Between
baseline and 12-month follow-up, 4/81 (4.9%) of the inter-
vention group versus 6/87 (6.9%) of the control group
underwent lower extremity revascularization. Results did not
substantially change when analyses were repeated after
excluding participants who underwent lower extremity revas-
cularization while they were enrolled in the GOALS trial (data
not shown).
When missing data were imputed, differences in rates of
mobility loss between the intervention and control group at 12-
month follow-up were no longer statistically significant (odds
ratio=0.36, 95% CI=+0.11 to +1.22, P=0.101). There were no
other meaningful changes in results when missing data were
imputed. When missing data were replaced with the worst
possible outcome for each measure, rates of mobility loss at
12-month follow-up were no longer significantly different
between the intervention and control groups (17.9% versus
24.3%, P=0.361). When missing data were replaced with the
worst possible outcome, rates of decline in the fast 4-m
walking velocity were no longer different between the
intervention and control groups at 6-month follow-up (0.02
versus0.08 m/s, P=0.100), and rates of decline in the SPPB
were no longer different between the intervention and control
groups at 12-month follow-up (0.81 versus1.00, P=0.695).
Discussion
The GOALS randomized trial demonstrated that a 6-month
GMCB intervention, designed to promote regular unsuper-
vised walking exercise in people with PAD, reduced the
exploratory outcome of mobility loss at 6-month follow-up,
compared to a control group. These differences persisted at
12-month follow-up, 6 months after the intensive phase of the
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Figure 3. Rates of mobility gain in the exercise and control groups among people with peripheral artery disease. Analyses are limited to
people with mobility loss at baseline.
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GMCB intervention was completed. As compared to the
control group, the GMCB intervention significantly reversed
mobility impairment that was present at baseline. This benefit
also persisted at 12-month follow-up. However, the GOALS
intervention did not improve usual-paced 4-m walking veloc-
ity, improved fastest-paced 4-m walking velocity only at
6-month follow-up, and improved the SPPB only at 12-month
follow-up.
Mobility loss was an exploratory outcome in the GOALS
trial. However, to our knowledge, the GOALS trial is the first
randomized trial to study whether any medical therapy
prevents self-reported mobility loss or improves self-reported
mobility loss in patients with PAD. Maintaining mobility is
integral to preserving functional independence, social inter-
actions, and activities of daily living.17–19 In contrast to
objective measures, which are assessed in a highly controlled
environment, self-reported mobility assesses participants’
perceptions of their functioning in the community. Preserva-
tion of mobility has implications for using public transporta-
tion and engaging in activities that are important for work,
play, and exercise.37 Older people who lose mobility have
higher rates of nursing home placement, morbidity, mortality,
depression, hospitalizations, chronic disease, and cognitive
impairment.16–22
Our results show that the GMCB intervention, designed to
promote home-based, unsupervised walking exercise,
improved a broad range of functional limitations in people
with PAD. In addition to its effect on mobility loss, the GMCB
intervention improved the exploratory outcomes of fast-paced
4-m walking speed at 6-month follow-up and the SPPB at
12-month follow-up. The SPPB is a measure of balance and
lower extremity strength. Poorer scores on the SPPB and in
walking velocity are associated with higher rates of cardiovas-
cular mortality and mobility loss in people with PAD.1,21 A
previous analysis used observational and clinical trial evidence
to link changes in the SPPB to changes in patient-reported
quality of life and mobility loss and defined a clinically
meaningful change in the SPPB as a change of 0.5 or greater.38
Thus, the 12-month change in SPPB in the intervention group
as compared to the control group was clinically meaningful. To
our knowledge, clinically meaningful change for the fast-paced
4-m walking velocity has not been defined.
Prior studies by Bendermacher et al and Kruidenier et al
assessed associations of supervised treadmill exercise ther-
apy delivered by physiotherapists for the outcome of
improved treadmill walking performance in PAD patients with
intermittent claudication.11,39 However, these studies were
not randomized controlled trials and outcome measures were
1
1.2
1.4
1.6
Baseline 6 Months 12 Months
Ve
lo
ci
ty
 (m
/s
)
Fast-paced four-meter walking velocity 
0
p value* = 0.005 p value** = 0.250
*6 month to baseline
** 12 month to baseline
Control group (N=87)
Exercise group 
(N=81)
0.7
0.8
0.9
1
1.1
Baseline 6 Months 12 Months
Ve
lo
ci
ty
 (m
/s
)
Normal-paced four-meter walking 
velocity
0
p value* = 0.080 p value** = 0.547
*6 month to baseline
** 12 month to baseline
Exercise group 
(N=81)
Control group (N=87)
8
9
10
11
12
13
Baseline 6 Months 12 Months
Sc
or
e
Short Physical Performance Baery Score
0
p value* = 0.086 p value** = 0.027
*6 month to baseline
** 12 month to baseline
Control group (N=83)
Exercise group 
(N=76)
Figure 4. Changes in functional performance in the exercise vs control groups among people with peripheral artery disease.
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not blinded. In contrast to the GOALS trial, supervised
exercise sessions in the trials by Bendermacher et al and
Kruidenier et al occurred 2 to 3 times per week for the first
3 months, a frequency that was tapered to once every
2 weeks at 6-month follow-up and once every 8 weeks for the
final 6 months of the intervention. Participants were also
advised to walk at home, but information on the frequency of
home exercise was not reported.11,39 Dropout rates were high
(60% follow-up rate at 6-months and 47% follow-up rate at
12 months). Among the PAD participants who did not drop
out, maximum treadmill walking distance increased by 191%
at 6-month follow-up and by 197% at 12-month follow-up.11,39
In contrast to these prior studies, the GOALS intervention
required a substantially lower rate of on-site exercise activity
during the first 3 months, used a randomized trial design,
included a GMCB intervention, and had substantially lower
dropout rates.
Study Limitations
The GOALS Study has limitations. First, the first 6 months of
the GOALS trial consisted of weekly visits to the medical
center and consisted of a somewhat complex GMCB
intervention that required both assembling a group of PAD
participants and a facilitator to lead each session. For these
reasons, the intervention may be difficult to implement in
clinical practice. Further study is needed to determine
whether the GOALS intervention is effective with fewer on-
site visits. Second, the GOALS trial included a large number of
exclusion criteria. Results may not be generalizable to people
with PAD who were excluded from participation, including
participants who were unwilling to attend weekly visits to the
exercise center. Third, our analyses included multiple com-
parisons. Our results require confirmation in other cohorts of
PAD participants. Fourth, we did not collect data on the cost
of the intervention. Fifth, we did not specifically collect data
from participants about the degree to which they value
mobility loss.
Conclusions
In conclusion, a GMCB intervention that promoted home-based
walking exercise reduced rates of self-reported mobility loss in
patients with PAD at 6-month follow-up. The home-based
exercise intervention improved self-reported mobility in
Table 2. Six- and 12-Month Changes in Each Component of the Short Physical Performance Battery Intervention Among
Peripheral Artery Disease Participants Enrolled in the Group Oriented Arterial Leg Study
Outcome Measures—6-Month
Comparisons N Baseline Mean (SD) 6-Month Mean (SD) Within-Group Change (95% CI) With-Control Comparison (95% CI) P Value
Walking velocity score (0 to 4 scale, 4=best)
Control group 87 3.61 (0.56) 3.66 (0.55) 0.05 (0.06 to 0.15) Reference group 0.5858
Intervention group 81 3.67 (0.61) 3.75 (0.56) 0.09 (0.02 to 0.19) 0.04 (0.11 to 0.19)
Standing balance score (0 to 4 scale, 4=best)
Control group 87 3.09 (1.00) 3.07 (1.09) 0.02 (0.26 to 0.21) Reference group 0.1596
Intervention group 80 3.01 (1.26) 3.24 (1.02) 0.23 (0.04 to 0.49) 0.25 (0.10 to 0.59)
Time for 5 chair rises (0 to 4 scale, 4=best)
Control group 83 3.19 (1.16) 3.19 (1.04) 0 (0.22 to 0.22) Reference group 0.3546
Intervention group 77 3.14 (1.16) 3.29 (1.10) 0.14 (0.07 to 0.36) 0.14 (0.16 to 0.45)
Outcome Measures—12-
Month Comparisons N Baseline Mean (SD) 12-Month Mean (SD) Within-Group Change (95% CI) With-Control Comparison (95% CI) P Value
Walking velocity score (0 to 4 scale, 4=best)
Control group 87 3.61 (0.56) 3.62 (0.60) 0.01 (0.11 to 0.13) Reference group 0.8799
Intervention group 81 3.67 (0.61) 3.69 (0.65) 0.02 (0.10 to 0.15) 0.01 (0.16 to 0.19)
Standing balance score (0 to 4 scale, 4=best)
Control group 87 3.09 (1.00) 2.97 (1.06) 0.13 (0.38 to 0.13) Reference group 0.0263
Intervention group 80 3.01 (1.26) 3.28 (1.01) 0.26 (0.03 to 0.49) 0.39 (0.05 to 0.73)
Time for 5 chair rises (0 to 4 scale, 4=best)
Control group 83 3.19 (1.16) 3.19 (1.18) 0 (0.23 to 0.23) Reference group 0.2656
Intervention group 77 3.14 (1.16) 3.31 (1.14) 0.17 (0.02 to 0.36) 0.17 (0.13 to 0.47)
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participants who reported mobility impairment at baseline. All
of these benefits persisted at 12-month follow-up, 6 months
after the intensive phase of the exercise intervention was
completed. Further study is needed to determine whether
interventions designed to increase home-based exercise and
that have fewer on-site visits improve walking performance and
prevent mobility loss in people with PAD.
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